Temasek Life Sciences Accelerator

What Temasek Life Sciences Accelerator does

Temasek Life Sciences Accelerator (TLA) is a Singapore-based life sciences accelerator and venture fund operating within the broader Temasek ecosystem. Incorporated as Temasek Life Sciences Accelerator Pte. Ltd., the company is closely affiliated with Temasek Life Sciences Laboratory (TLL), co-locating at 1 Research Link on the National University of Singapore campus and sharing senior leadership — Peter Chia serves as CEO of both TLA and TLL, while Niam Chiang Meng chairs the TLA board alongside Professor Low Teck Seng (NUS Senior Vice President, Sustainability and Resilience) and Deputy CEO Dr. Lee Ker Yin.

TLA delivers its offering through two integrated products. The Hatchery is a 12-month extendable incubation program providing early-stage life sciences startups with dedicated lab space, office workstations for up to three people, and access to specialized GLP-compliant laboratory equipment and shared technology infrastructure. The Lifesciences Innovation Fund (TLIF) deploys catalytic capital — typically up to S$500K per company — at pre-seed, seed, or Series A stages, targeting startups with valuations not exceeding S$10M. TLA's investment thesis is concentrated across three verticals: healthspan extension, nutritional security, and sustainability.

The company's go-to-market is event-driven and application-based: startups apply directly to the Hatchery program or pursue TLIF funding through the website's inquiry channels. TLA generates returns via equity upside on TLIF portfolio investments rather than recurring service fees, and the firm does not publicly disclose revenue. With over 40 portfolio companies across aquaculture (Aqualita), sustainable materials (MYCL), rice innovation (Temasek Rice), diagnostics (Pathnova), and AI-driven biomanufacturing (ChemT Biotechnology), TLA operates at venture-fund scale with a headcount of 1-10 employees and negligible direct technology development.

Name

Temasek Life Sciences Accelerator

Legal name

Temasek Life Sciences Accelerator Pte. Ltd.

Website

https://tla.com.sg

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Life Sciences Accelerator and Venture Capital

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Life sciences incubation
• Early-stage investment
• Biotech accelerator
• Venture building support
• Catalytic capital

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Returns from TLIF: TLA generates returns through equity investments in early-stage life science companies via The Life Sciences Innovation Fund (TLIF), ranging from pre-seed to Series A stages with investments up to 500K per company.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Temasek Life Sciences Accelerator (TLA) is a life sciences accelerator and venture fund that incubates and invests in early-stage life sciences startups. It runs The Hatchery, a 12-month extendable incubator program providing dedicated lab space, office workstations, shared specialized equipment, and venture building support including fundraising, investor introductions, and grant application guidance. It also deploys catalytic capital through The Lifesciences Innovation Fund (TLIF), issuing equity investments of up to S$500K at pre-seed, seed, or Series A stages to startups in sustainability, nutritional security, and healthspan extension.

Product overview

Temasek Life Sciences Accelerator (TLA) is a life sciences accelerator and investment fund offering two integrated programs: The Hatchery incubation program providing specialized lab facilities, workspace, and venture-building support over 12 months, and The Lifesciences Innovation Fund (TLIF) providing catalytic capital investments from pre-seed to Series A stages. TLA focuses on innovations in healthspan extension, nutritional security, and sustainability.

Differentiator

Problem solved

Functional benefit

Products and services

• The Hatchery A 12-month extendable incubator program for early-stage life sciences startups, providing access to dedicated laboratory space, office workstations, shared specialized equipment, and hands-on venture building support including fundraising assistance, investor connections, reference clients, grant application guidance, and consideration for TLIF funding. It targets founding teams in sustainability, nutritional security, and healthspan extension.
• The Lifesciences Innovation Fund (TLIF) A catalytic capital investment fund that deploys equity investments of up to S$500K into early-stage life sciences companies at pre-seed, seed, or Series A stages. It targets startups with at least an MVP and prefers valuations not exceeding S$10M, and is open to all deal structures.

Quantifiable outcome

• 12-month extendable Hatchery program with lab space and office workstation up to 3 pax
• +1 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• Temasek Life Sciences Laboratory (TLL)coreStrategic or Co-development PartnerTLL is the parent organization and research arm providing scientific expertise, collaboration with scientists, and technical infrastructure support. TLA CEO also serves as CEO of TLL, and TLA taps on TLL's critical lab facilities and infrastructure for the Hatchery program.
• PAAminorOthersPartner organization listed on TLA website with logo displayed in the partners section.
• CHIminorOthersPartner organization listed on TLA website with logo displayed in the partners section.
• NHICminorOthersPartner organization listed on TLA website with logo displayed in the partners section.
• LCminorOthersPartner organization listed on TLA website with logo displayed in the partners section.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• BioInnovation Institute (BII): Denmark-based life sciences incubator and venture fund providing lab facilities, business acceleration, and seed/Series A capital to biotech, medtech, and pharma startups. Comparable to TLA in integrating infrastructure provision with catalytic investment in early-stage life sciences.
• IndieBio (SOSV): SOSV's biotech-focused accelerator program providing lab infrastructure, mentorship, and seed funding to early-stage life sciences and biotech startups globally. Most directly comparable to TLA in combining catalytic capital with deep domain expertise and shared lab facilities.
• BioGenerator: St. Louis-based biotechnology and agri-tech accelerator and investor that combines venture funding with laboratory infrastructure for early-stage companies. Highly comparable to TLA's dual investor + incubator model with similar check sizes and pre-seed to Series A focus.
• MBC BioLabs: San Francisco-based biotech incubator offering shared lab space, equipment, and venture-building support to early-stage life sciences startups. Directly comparable to TLA's Hatchery model of providing specialized wet-lab infrastructure alongside programmatic support.

Broad incumbents

• JLABS (Johnson & Johnson Innovation): Johnson & Johnson's global network of life sciences incubators providing lab space, equipment, and mentorship to biotech startups. Comparable to TLA's incubator model but operates at much larger scale as part of a major pharmaceutical corporation's external innovation strategy.
• Y Combinator: The largest global startup accelerator, which launched YC Bio to focus specifically on life sciences companies. Comparable in accelerator/incubator structure but generalist in scope, with life sciences as one of several verticals.
• Flagship Pioneering: Cambridge, MA-based venture creation firm that originates and funds breakthrough life sciences companies from inception through commercial stages. Comparable to TLA's venture-building approach but at significantly larger scale and with broader life sciences coverage including the founding of Moderna.

Regional players

• A*ccelerate (A*STAR): Singapore-based technology transfer and commercialization arm of A*STAR (Agency for Science, Technology and Research). Directly comparable to TLA as another Singapore life sciences commercialization entity with shared access to public research infrastructure and government co-funding.

Emerging players

• Plug and Play Tech Center: Global innovation platform and accelerator running multiple industry-specific programs including Health and Biotech verticals. Comparable to TLA in providing accelerator infrastructure and venture-building support, though with broader industry focus across fintech, insurtech, brand, and retail.
• Creative Destruction Lab: Global seed-stage accelerator with a dedicated Biotech stream partnering with leading universities to commercialize science-based ventures. Comparable to TLA in targeting early-stage, science-driven startups through structured program delivery, though with broader geographic coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Temasek Life Sciences Accelerator